Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-week, Multicenter, Randomized, Open-Label, Parallel-group Study Comparing the Efficacy and Safety of Toujeo and Tresiba in Insulin-NaivePatients With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Next Previous
Trial Profile

A 24-week, Multicenter, Randomized, Open-Label, Parallel-group Study Comparing the Efficacy and Safety of Toujeo and Tresiba in Insulin-NaivePatients With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin degludec
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms BRIGHT
  • Sponsors Sanofi

Most Recent Events

  • 01 Jul 2021 Results of subanalysis assessing efficacy and safety of Gla-300 versus IDeg-100 in predefined (less than or greater than equal to 65 years) and post hoc (less than or greater than equal to 70 years) age group with type 2 diabetes, published in the Diabetes, Obesity and Metabolism.
  • 25 Sep 2020 Results from real-world studies ACHIEVE, REACH, REGAIN, and RCTs EDITION 1-3 and BRIGHT assessing Treatment satisfaction in people with type 2 diabetes receiving basal insulin, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
  • 06 Dec 2019 Results of post-hoc analysis assessing HbA1c change and incidence and rates of hypoglycaemia presented at the 2019 Congress of the International Diabetes Federation.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top